

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Comparison of fast versus ultraslow infusion of thrombolytic in patients with mechanical prosthetic valve thrombosis- A randomized controlled trial

Protocol summary

Study aim

Comparison of fast versus ultraslow infusion of thrombolytic regimen in patients with mechanical prosthetic valve thrombosis

Design

Two parallel groups randomized trial with blinded outcome assessment

Settings and conduct

The trial will be held in a hospital setting (Rajaie Cardiovascular Medical and Research center) on patients with mechanical prosthetic valve thrombosis. Patients will be randomized via central web based method into two interventional groups with two different thrombolytic regimen. Treating physician and patients will not be blinded. Thrombus resolution and degree of valve opening will be evaluated by echocardiography after thrombolytic therapy. Also thrombolytic complication will be evaluated during hospitalization.

Participants/Inclusion and exclusion criteria

Inclusion criteria: provision of signed and dated informed consent form; patients with prosthetic mechanical valve thrombosis approved by echocardiography; men and women ≥ 18 year-old. Exclusion criteria: contraindication of thrombolytic therapy; dyspnea of functional class 4; thrombus size larger than 0.8 cm².

Intervention groups

In this study there are two interventional groups: first group: patients will receive fast thrombolytic regimen. Second group: patients will receive ultra slow thrombolytic regimen.

Main outcome variables

Degree of valve opening; thrombus size; clinical functional class; bleeding; thromboembolic complications

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20181022041406N2**

Registration date: **2019-04-03, 1398/01/14**

Registration timing: **registered_while_recruiting**

Last update: **2021-12-11, 1400/09/20**

Update count: **1**

Registration date

2019-04-03, 1398/01/14

Registrant information

Name

Parham Sadeghipour

Name of organization / entity

Rajaie Cardiovascular Medical and Research Center

Country

Iran (Islamic Republic of)

Phone

+98 21 2392 2092

Email address

psadeghipour@hotmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-07-23, 1397/05/01

Expected recruitment end date

2020-04-20, 1399/02/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of fast versus ultraslow infusion of thrombolytic in patients with mechanical prosthetic valve thrombosis- A randomized controlled trial

Public title

Thrombolytic in mechanical prosthetic valve thrombosis

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Provision of signed and dated informed consent form
Patients with prosthetic mechanical valve thrombosis approved by echocardiography Men and women \geq 18 year-old

Exclusion criteria:

Contraindication of thrombolytic therapy
Dyspnea of functional class 4
Thrombus size larger than 0.8 cm²

Age

From **18 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **120**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization will be performed via permuted block randomization method. Allocation will be generated via a web based system and consequently concealment will be central using computer software. Unit of randomization will be individual patients and no stratification will be applied.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Rajaie Cardiovascular Medical and Research Center
Ethic committee

Street address

Vali-Asr ave, Hashemi Rafsanjani Exp

City

Tehran

Province

Tehran

Postal code

1995614331

Approval date

2018-06-30, 1397/04/09

Ethics committee reference number

IR.RHC.REC.1397.022

Health conditions studied**1****Description of health condition studied**

Mechanical prosthetic valve thrombosis

ICD-10 code

T82.0

ICD-10 code description

Mechanical complication of heart valve prosthesis

Primary outcomes**1****Description**

Degree of valve opening

Timepoint

Hospitalization

Method of measurement

Echocardiography

2**Description**

Thrombus size

Timepoint

Hospitalization

Method of measurement

Echocardiography

3**Description**

Clinical functional class

Timepoint

Hospitalization

Method of measurement

Questionnaire

Secondary outcomes**1****Description**

Bleeding

Timepoint

Hospitalization

Method of measurement

CT angiography

2**Description**

Thromboembolic events
Timepoint
Hospitalization
Method of measurement
CT angiography

Intervention groups

1

Description
Intervention group: Fast thrombolytic regimen
Category
Treatment - Drugs

2

Description
Intervention group: ultraslow thrombolytic regimen
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Rajaie cardiovascular medical and research center
Full name of responsible person
Parham Sadeghipour
Street address
Vali-Asr ave, Hashemi Rafsanjani Exp
City
Tehran
Province
Tehran
Postal code
1995614331
Phone
+98 21 2392 2092
Email
psadeghipour@rhc.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Rajaie cardiovascular medical and research center
Full name of responsible person
Feridoun Nouhi
Street address
Vali-Asr Ave, Hashemi Rafsanjani Exp
City
Tehran
Province
Tehran
Postal code
1995614331
Phone

+98 21 2392 2020

Email
fnoohi@rhc.ac.ir

Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Rajaie cardiovascular medical and research center
Proportion provided by this source
100

Public or private sector
Public
Domestic or foreign origin
Domestic

Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Rajaie cardiovascular medical and research center
Full name of responsible person
Parham Sadeghipour
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Cardiology
Street address
Vali-Asr Ave, Hashemi Rafsanjani Exp
City
Tehran
Province
Tehran
Postal code
1995614331
Phone
+98 21 2392 2092
Email
psadeghipour@rhc.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Rajaie cardiovascular medical and research center
Full name of responsible person
Parham Sadeghipour
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work
Cardiology

Street address

Vali-Asr Ave, Hashemi Rafsanjani Exp

City

Tehran

Province

Tehran

Postal code

1995614331

Phone

+98 21 2392 2092

Email

psadeghipour@rhc.ac.ir

Tehran

Postal code

1995614331

Phone

+98 21 2392 2092

Email

psadeghipour@rhc.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Rajaie cardiovascular medical and research center

Full name of responsible person

Parham Sadeghipour

Position

Assistant professor

Latest degree

Subspecialist

Other areas of specialty/work

Cardiology

Street address

Vali-Asr Ave, Hashemi Rafsanjani Exp

City

Tehran

Province**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Trial results**Please tick if results have been published**

Yes

Summary result posting date

2021-12-11, 1400/09/20

Table of baseline comparison**Participant flow diagram****Table of variable outcomes' results****Table of adverse events****First publication date**

2021-12-04, 1400/09/13

Abstract of published paper

Background Thrombolysis is an alternative to surgery for mechanical prosthetic valve thrombosis (MPVT). Randomized clinical trials have yet to test safety and efficacy of a proposed ultraslow thrombolytic infusion regimen. Methods and Results This single-center, open-label, pilot randomized clinical trial randomized adult patients with acute obstructive MPVT to an ultraslow thrombolytic regimen (25 mg of recombinant tissue-type plasminogen activator [rtPA] infused in 25h) and a fast thrombolytic regimen (50 mg of rtPA infused in 6h). If thrombolysis failed, a repeated dose of 25 mg of rtPA for 6h was administered in both groups up to a cumulative dose of 150 mg or the occurrence of a complication. Primary outcome was a complete MPVT resolution (>75% fall in the obstructive gradient by transthoracic echocardiography, <10° limitation in opening and closing valve motion angles by fluoroscopy, and symptom improvement). Key safety outcome was a BARC type III or V major bleeding. Overall, 120 patients, including 63 (52.5%) women, at a mean age of 36.3±15.3 years, were randomized. Complete thrombolysis success was achieved in 51 patients (85.0%) in the ultraslow-regimen group and 47 patients (78.3%) in the fast-regimen group (OR, 1.58; 95% CI, 0.25 to 1.63; P = 0.34). One case of transient ischemic attack and 3 cases of intracranial hemorrhage (absolute risk difference, -12.5%; 95% CI, -23.1% to -1.0%; P = 0.04). were observed only in the fast-regimen group. Conclusions The ultraslow thrombolytic regimen conferred a high thrombolysis resolution rate without major complications. Such findings should be replicated in more adequately powered trials (IRCT20181022041406N2).